Last update Dec. 16, 2022

Bictegravir

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Bictegravir is an integrase inhibitor used to treat HIV infection and AIDS. Oral administration once daily in fixed-dose combination with tenofovir alafenamide fumarate (TAF) and emtricitabine (FTC).

It is excreted in breast milk in clinically insignificant amounts. (Aebi 2022)

Plasma levels in an infant were 2% of maternal plasma levels. (Aebi 2022)

 

One of these antiretroviral treatment (ART) regimens is recommended for nursing mothers diagnosed with acute HIV infection (Panel USA 2022):

  • Bictegravir (BIC) + tenofovir alafenamide (TAF) + emtricitabine (FTC): BiktarvyTM
  • Dolutegravir (DTG) + TAF or tenofovir fumarate (TDF) + emtricitabine (FTC) or lamivudine (3TC)
  • Boosted Darunavir (DRV) + TAF or TDF + FTC or 3TC: SymtuzaTM 

 


See below the information of this related product:

Alternatives

We do not have alternatives for Bictegravir since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Bictegravir in other languages or writings:

  • بيكتيغرافير (Arabic)
  • Биктегравир (Cyrillic)
  • 比克替拉韦 (Chinese)
  • (2R,5S,13aR)-8-Hydroxy-7,9-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide (Chemical name)
  • C21H18F3N3O5 (Molecular formula)
  • J05AR20 (ATC Code/s)

Group

Bictegravir belongs to this group or family:

Tradenames

Main tradenames from several countries containing Bictegravir in its composition:

  • Biktarvy™. Contains other elements than Bictegravir in its composition

Pharmacokinetics

Variable Value Unit
Oral Bioavail. > 70 %
Molecular weight 449 daltons
Protein Binding > 99 %
VD 0.2 l/Kg
Tmax 2 - 4 hours
17.3 hours
M/P ratio 0.01 -
Theoretical Dose 0.01 mg/Kg/d
Relative Dose 1.2 %

References

  1. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Department of Health and Human Services. 2023 Consulted on June 16, 2023 Abstract Full text (link to original source)
  2. Aebi-Popp K, Kahlert CR, Crisinel PA, Decosterd L, Saldanha SA, Hoesli I, Martinez De Tejada B, Duppenthaler A, Rauch A, Marzolini C; Swiss Mother and Child HIV Cohort Study (SHCS).. Transfer of antiretroviral drugs into breastmilk: a prospective study from the Swiss Mother and Child HIV Cohort Study. J Antimicrob Chemother. 2022 Nov 28;77(12):3436-3442. Consulted on Dec. 16, 2022 Abstract Full text (link to original source)
  3. Zeuli J, Rizza S, Bhatia R, Temesgen Z. Bictegravir, a novel integrase inhibitor for the treatment of HIV infection. Drugs Today (Barc). 2019 Nov;55(11):669-682. Consulted on Dec. 16, 2022 Abstract

Total visits

733

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM